# Retatrutide’s Phase 2 tests measured weight loss alongside unwanted effects > Retatrutide: People lost weight; lasting safety is unsettled — Research Peptide Fundamentals research peptides: retatrutide’s Phase 2 trials found weight loss. Learn about unwanted effects and the gaps in lasting safety. **WEIGHT CHECKS IN PEOPLE / 03** Retatrutide copies GIP, GLP-1, and glucagon, hormones involved in hunger, sugar, and energy. This page explains the human results and the safety questions left open. ## The brief answer: people benefited, but lasting effects remain uncertain Retatrutide combines copies of three natural hormone actions in one peptide. You can read the human findings here, with the later checks still missing. When blood sugar rises, GIP and GLP-1 help the body release insulin. GLP-1 also affects hunger, while insulin lets cells remove sugar from your blood. That insulin action lowers your blood sugar. GIP also affects hunger. Glucagon's part aims to release stored fat and make the body use more energy. Lab tests found retatrutide attaching where these three hormones normally act [14]. Lab attachment leaves the question of lasting improvement in your health unanswered. Unlike KPV, retatrutide has human trials comparing different treatment groups. Phase 2 is an early check in people for benefits and unwanted effects. These tests concerned obesity, type 2 diabetes, and fatty liver disease [15][16][17]. Weight, blood sugar, and liver fat fell in some treated groups. Those findings haven't led to approval and don't settle lasting heart or kidney effects. You still need answers about what happens over more time. The Phase 2 studies reported stomach or bowel trouble and faster heart rates [13][16]. **Benefits were measured in people, while lasting benefit and harm remain uncertain.** Products outside the trials haven't been checked as matching the trial treatment. A study result doesn't establish what's inside a different bottle. ## One retatrutide peptide combines the actions of three hormones Retatrutide, also called LY3437943, is a 39-amino-acid peptide: thirty-nine small protein ingredients linked together. Researchers used GIP, a hormone involved in handling food, as their starting point. They changed the peptide and gave it an added part made from fat. Its attachment to blood protein slows retatrutide’s removal from the body [13][14]. Three hormone actions don't mean three separate medicines mixed in a bottle. Retatrutide is one peptide acting where GIP, GLP-1, and glucagon normally act. The design aims to change hunger, use of energy, and sugar in blood. You need tests in people to establish how much those changes help. ## Hormone actions change sugar levels and the stomach’s emptying GLP-1 slows the stomach's emptying and helps reduce hunger after meals. This hormone also helps send out insulin after a rise in blood sugar and curbs glucagon after eating. Insulin brings blood sugar down by helping sugar enter cells. GIP helps the body release insulin as blood sugar rises too. Researchers think GIP may add to changes in hunger and energy use. Glucagon can release stored fat and increase energy used by the body. That glucagon action leaves questions for you about heartbeat and blood sugar. Lab experiments can't establish how much a person's health would improve. A special microscope showed retatrutide attached where the three hormones normally act [14]. Retatrutide’s strength in those tests differed from the natural hormones’ strength. I keep that lab finding separate from how people responded in trials. An attachment seen under a microscope can't tell you about lasting health. ## Early trials found lower weight, sugar readings, and liver fat These early trials don't establish your own likely weight loss. A Phase 2 obesity trial assigned 338 adults to groups by chance [16]. At 48 weeks, the largest study amount brought an average weight loss of 24.2% from starting weight. The placebo group lost 2.1%; placebo contained no tested medicine. The figures describe shares of starting weight, rather than pounds. Most stomach or bowel trouble was mild or moderate, with more trouble at larger amounts. Faster heart rates also increased with study amounts, peaking at 24 weeks [16]. Another Phase 2 trial involved 281 adults with type 2 diabetes. One treated group's blood-sugar test improved at 24 weeks. Separately, weight checks found weight loss at 36 weeks. The placebo group had smaller changes in blood sugar and weight [17]. Stomach and bowel problems affected 35% of participants and were mild or moderate [17]. There were no deaths or episodes of dangerously low blood sugar. A Phase 2a test involved 98 people who had fatty liver disease and excess weight. After 24 weeks, one group's liver fat had fallen substantially. Of those people, 86% reached the study's normal liver-fat level [15]. Normal meant that fat made up less than 5% of the liver. One percentage counts people; the other describes liver fat. A review discusses Phase 1, the first limited human safety checks [13]. Phase 2 checks early benefits too; stomach trouble and faster heart rates remained concerns. Phase 3 uses larger groups for fuller checks of benefits and harm. Those trials were ongoing in these papers. ## Personal accounts lack the checks used in treatment trials **People trying retatrutide for research describe changes noticed afterward. These personal accounts have no controlled trial confirming the experience or checking its cause.** People often report less hunger, fewer thoughts about food, and quick weight loss. Nausea and tiredness early on are also frequent reports. Other accounts mention warmth, a faster resting heartbeat, constipation, belching, and itching. Poor sleep, mood changes, and a softer or less muscular appearance also appear. You don't learn from the accounts how often everyone trying retatrutide has these experiences. Meals, illness, other medicines, or expectations may contribute to what someone notices. An uncertain bottle's contents create a further question about the reported experience. The accounts can't establish that the person received the same peptide as trial participants. In the obesity trial, larger study amounts brought more stomach trouble and faster heart rates [16]. The diabetes trial also reported stomach and bowel problems [17]. People losing weight quickly may lose muscle along with fat. These papers don't establish how much muscle was lost. A doctor needs your medical history to assess medicine conflicts or unsuitable treatment. Retatrutide lacks approval; effects on heart and kidneys over more time remain unknown. What happens after treatment ends also needs more checking. Products outside a registered trial lack the trial's checks on contents and care. Quoting a trial doesn't establish the same checks for an advertised bottle. You can't assume an advertised bottle matches the treatment studied. ## More human evidence still leaves retatrutide short of settled safety Retatrutide’s human benefit tests have gone further than those of these other peptides. You still don't have settled answers about lasting safety. Phase 2 treatment groups included people who had obesity, diabetes, or fatty liver disease. Phase 3 uses larger groups for fuller checks of benefits and harm. Longer studies need to follow people after treatment has ended too. For you, benefits lasting and new problems emerging are separate questions. Retatrutide combines several hormone actions within one peptide. The missing answers still matter alongside the human findings. The GHK-Cu page turns to studies of products placed on skin. Applying a cream doesn't establish what the same peptide would do as a shot. ![Retatrutide research illustration](/images/retatrutide.webp) --- Alien Peptide is an independent briefing on unfamiliar peptide classes, mechanisms, and evidence limits—not a clinic, vendor, or source of medical advice.